Loading
Latest filing published 28 Nov 2024 for XSpray Pharma AK, €2,929.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Per Andersson discloses dealings in 2 companies, chiefly XSpray Pharma AK and XSpray Pharma AB (publ). We count 19 filings; the first trade dates from 27 September 2017 and the latest from 28 November 2024.
Both buying and selling appear: 5 purchases worth €107k, against 5 sales worth €709k. The totals do not cover 1 filing with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2024 to date brings 1 purchase and 2 sales.
The median purchase comes to €18k.
The newest entry dates from 28 November 2024: an open-market sale of €2,929, in XSpray Pharma AK. The most recent open-market purchase was published on 29 May 2024, 877 days ago. Typically, a trade is published a median of 2 days after it takes place. The regulation allows three business days to notify a trade (MAR article 19). These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations